Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Ascletis Pharma Inc. ASCLF OTC

Other OTC • Healthcare • Biotechnology • CN • USD

SharesGrow Score
31/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Ascletis Pharma Inc. (ASCLF) is a Biotechnology company in the Healthcare sector, currently trading at $2.10. It has a SharesGrow Score of 29/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $1M, -40.9%/yr average growth. Net income is $301M (loss), growing at -42.9%/yr. Net profit margin is -23455.7% (negative). Gross margin is 57.3% (+6.3 pp trend).

Balance sheet: total debt is $8M against $2.0B equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 12.88 (strong liquidity). Debt-to-assets is 0.4%. Total assets: $2.1B.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 62/100 (Partial), Future ?/100 (Fail), Income 10/100 (Fail).

ASCLF SharesGrow Score Overview

39/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 62/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ASCLF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
ASCLF: -40.9%/yr revenue is, -42.9%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ASCLF: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 12.88 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
62/100
ASCLF: Gross margin is 57.3% (+6.3 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 62/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
ASCLF: Net profit margin is -23455.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.6217-2.29
Volume450
Avg Volume (30D)895
Market Cap$2.22B
Beta (1Y)0.59
Share Statistics
EPS (TTM)-0.30
Shares Outstanding$1B
IPO Date2019-11-19
Employees231
CEOJinzi Jason Wu
Financial Highlights & Ratios
Revenue (TTM)$1.28M
Gross Profit$735K
EBITDA$-280.24M
Net Income$-300.94M
Operating Income$-382.26M
Total Cash$1.95B
Total Debt$7.63M
Net Debt$-858.1M
Total Assets$2.12B
Price / Earnings (P/E)-7
Price / Sales (P/S)1727.38
Analyst Forecast
Company Info
CountryCN
ExchangeOther OTC
CurrencyUSD
ISINKYG0520K1094

Price Chart

Track all markets on TradingView
ASCLF
Ascletis Pharma Inc. ↗  ·  Other OTC
Healthcare • Biotechnology
0.62 52WK RANGE 2.29

People Also View

BCDAW
BCDAW
BioCardia, Inc.
$0.01
-3.17%
 ADYX
ADYX
Adynxx, Inc.
$0.00
+0.00%
 ADILW
ADILW
Adial Pharmaceuticals, Inc. WT EXP 073123
$0.00
-57.14%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message